Back to Directory Collin Delgado Email delgado@frontierscience.org Institution Frontier Science Foundation Request an Update Affiliated Studies IMPAACT 2050: Phase IV Study of the Pharmacokinetics of Long-Acting Injectable Cabotegravir and Rilpivirine in Pregnant and Postpartum Women with HIV in the United States DAIDS Number 39208 Research Area Treatment Study Status In Development
IMPAACT 2050: Phase IV Study of the Pharmacokinetics of Long-Acting Injectable Cabotegravir and Rilpivirine in Pregnant and Postpartum Women with HIV in the United States DAIDS Number 39208 Research Area Treatment Study Status In Development
